Know Cancer

or
forgot password

Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea


Phase 2
18 Years
N/A
Not Enrolling
Both
Metastatic Colorectal Cancer

Thank you

Trial Information

Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea


Inclusion Criteria:



- metastatic colorectal cancer to be treated with FOLFIAT chemo

Exclusion Criteria:

- severely abnormal liver and kidney function

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Reduction in diarrhea.

Outcome Time Frame:

Study completion

Safety Issue:

No

Principal Investigator

Michael Sawyer, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Health Services

Authority:

Canada: Health Canada

Study ID:

GI-05-0024

NCT ID:

NCT00255229

Start Date:

December 2002

Completion Date:

January 2010

Related Keywords:

  • Metastatic Colorectal Cancer
  • irinotecan
  • 5FU
  • amino acids
  • heat shock protein
  • Colorectal Neoplasms
  • Diarrhea

Name

Location